Why the study?
Current evidence was summarized to determine a possible genotype-phenotype association among individuals with Nager syndrome.
Are SF3B4 variants associated with specific clinical phenotypes in Nager syndrome?
Are SF3B4 variants associated with specific clinical phenotypes in Nager syndrome?
Frameshift variants in SF3B4 leading to nonsense-mediated RNA decay may be associated with more severe clinical manifestations in Nager syndrome, including a higher proportion of cardiac malformations for variants in exons 2 and 3.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for SF3B4 genotype-phenotype links in Nager syndrome; leaves open prospective validation before clinical use.
Nager syndrome (NS) is a rare disease marked with craniofacial and preaxial limb anomalies. In this report, we summarized the current evidence to determine a possible genotype-phenotype association among NS individuals. Twenty-four articles comprising of 84 NS (including 9 patients with a severe form of NS [Rodriguez syndrome]) patients were examined, of which 76% were caused by variants in SF3B4 (OMIM *605593, Splicing Factor 3B, Subunit 4). Within the SF3B4 gene, variants located in exon 3 commonly occurred (20%) from a total identified variant, while hotspot location was identified in exon 1 (12%), and primarily occurred as frameshift variants (64%). Thirty-five distinct pathogenic variants within SF3B4 gene were identified with two common sites, c.1A > G and c.1060dupC in exons 1 and 5, respectively. Although no significant genotype-phenotype association was found, it is notable that patients with frameshift SF3B4 variants and predicted to lead to nonsense-mediated RNA decay (NMD) of the transcripts tended to have a more severe clinical manifestation. Additionally, patients harboring variants in exons 2 and 3 displayed a higher proportion of cardiac malformations. Taken together, this article summarizes the pathogenic variants observed in SF3B4 and provides a possible genotype-phenotype relationship in this disease.
No takes yet. Share an insight, caveat, or question.
Ulhaq et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: